Trial Questions Continuous Maintenance in Newly Diagnosed Myeloma

(MedPage Today) -- Maintenance therapy with continuous lenalidomide (Revlimid) did not significantly improve overall survival (OS) in patients with standard-risk, newly diagnosed multiple myeloma, the phase III ENDURANCE trial showed.
Among patients...